Between 2010 and 2019, 63 MM patients received DT-PACE/ESHAP containing regimens: 42 (67%) for primary refractory, and 21 (33%) for relapsed disease including five patients who had previously received ASCT. One series reports that those able to receive ASCT fared better, suggesting that these patients still benefit from ASCT.12 Our data show a clear distinction in outcomes between patients who were consolidated with ASCT post DT-PACE/ESHAP (mostly primary refractory), I versus i the rest. This is the largest UK dataset of MM patients treated with DT-PACE/ESHAP reported to date, and confirms that even with current novel therapy, traditional infusional regimens retain a role in patients with high risk disease and are well tolerated. Chemotherapy regimens used for induction therapy [all patients and primary refractory patients proceeding to autologous stem cell transplant (ASCT) post ESHAP/PACE].Table SII. [Extracted from the article]